VIA Pharmaceuticals Completes Patient Visits In Phase 2 Carotid Endarterectomy (CEA) Trial

 11.07.2008 05:14   medicalnewstoday.com

VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced that it has completed the last patient visit in its carotid endarterectomy (CEA) study. The excised carotid plaque tissue will be analyzed to determine VIA-2291's effect on inflammation, and the company remains on track to report top-line data in the third quarter.

World Cardiology